(Q27665673)

English

Structure-based development of a receptor activator of nuclear factor- B ligand (RANKL) inhibitor peptide and molecular basis for osteopetrosis

scientific article

In more languages

Statements

scholarly article

0 references

Structure-based development of a receptor activator of nuclear factor- B ligand (RANKL) inhibitor peptide and molecular basis for osteopetrosis (English)

0 references

Tumor necrosis factor receptor superfamily, member 11a, NFKB activator

1 reference

GOA release 2020-03-11

Giang Thi Tuyet Nguyen

2

object named as

Giang Thi Tuyet Nguyen

author given names

Giang Thi Tuyet

author last names

Nguyen

1 reference

19 October 2023

author name string

Hai Minh Ta

1

author given names

Hai Minh

author last names

Ta

1 reference

19 October 2023

Hye Mi Jin

3

author given names

Hye Mi

author last names

Jin

1 reference

19 October 2023

Jongkeun Choi

4

author given names

Jongkeun

author last names

Choi

1 reference

19 October 2023

Hyejin Park

5

author given names

Hyejin

author last names

Park

1 reference

19 October 2023

Nacksung Kim

6

author given names

Nacksung

author last names

Kim

1 reference

19 October 2023

Hye-Yeon Hwang

7

author given names

Hye-Yeon

author last names

Hwang

1 reference

19 October 2023

Kyeong Kyu Kim

8

author given names

Kyeong Kyu

author last names

Kim

1 reference

19 October 2023

language of work or name

0 references

publication date

23 November 2010

0 references

Proceedings of the National Academy of Sciences of the United States of America

0 references

107

0 references

47

0 references

20281-6

0 references

Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2996688

20 March 2017

Crystal structure of the extracellular domain of mouse RANK ligand at 2.2-A resolution

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2996688

20 March 2017

Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2996688

20 March 2017

Crystal structure of TRAIL-DR5 complex identifies a critical role of the unique frame insertion in conferring recognition specificity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2996688

20 March 2017

Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2996688

20 March 2017

Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2996688

20 March 2017

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2996688

20 March 2017

Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2996688

20 March 2017

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2996688

20 March 2017

Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2996688

20 March 2017

Disabling of receptor activator of nuclear factor-kappaB (RANK) receptor complex by novel osteoprotegerin-like peptidomimetics restores bone loss in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2996688

20 March 2017

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2996688

20 March 2017

Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2996688

20 March 2017

Osteoclast differentiation and activation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2996688

7 April 2017

Genetic regulation of osteoclast development and function

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2996688

7 April 2017

RANK, RANKL and osteoprotegerin in bone biology and disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2996688

29 September 2017

CLINICAL Review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2996688

29 September 2017

An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2996688

29 September 2017

Mixed metastatic lung cancer lesions in bone are inhibited by noggin overexpression and Rank:Fc administration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2996688

29 September 2017

A TNF receptor loop peptide mimic blocks RANK ligand-induced signaling, bone resorption, and bone loss

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2996688

29 September 2017

Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2996688

29 September 2017

The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2996688

29 September 2017

Tumor necrosis factor family ligand-receptor binding

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2996688

29 September 2017

Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2996688

29 September 2017

Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL.

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.1011686107

21 January 2018

A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.1011686107

21 January 2018

Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.1011686107

21 January 2018

Randomized Active-Controlled Phase II Study of Denosumab Efficacy and Safety in Patients With Breast Cancer-Related Bone Metastases

1 reference

https://pubmed.ncbi.nlm.nih.gov/21059944

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1073/PNAS.1011686107

0 references

2010PNAS..10720281T

0 references

0 references

0 references

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q27665673&oldid=1993818681"